{"classes":[{"categories":[{"measurements":[{"comment":"The median was not reached and therefore, the median could not be calculated.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median was not reached and therefore, the median could not be calculated.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2061"},{"groupId":"OG001","value":"2075"}],"units":"Participants"}],"description":"Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.","dispersionType":"95% Confidence Interval","groups":[{"description":"2.5 mg by mouth (p.o.) once daily","id":"OG000","title":"Letrozole"},{"description":"1 mg p.o. once daily","id":"OG001","title":"Anastrozole"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) - the ITT contained randomized participants who had no protocol deviations.","reportingStatus":"POSTED","timeFrame":"84 months","title":"Time to Development of Contra Lateral Breast Cancer","type":"SECONDARY","unitOfMeasure":"Months"}